Prosecution Insights
Last updated: April 19, 2026
Application No. 17/908,622

HERBICIDAL PHENYLURACILS

Non-Final OA §102
Filed
Sep 01, 2022
Examiner
LIU, SUE XU
Art Unit
1616
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
1 (Non-Final)
21%
Grant Probability
At Risk
1-2
OA Rounds
5y 0m
To Grant
34%
With Interview

Examiner Intelligence

Grants only 21% of cases
21%
Career Allow Rate
46 granted / 221 resolved
-39.2% vs TC avg
Moderate +13% lift
Without
With
+12.9%
Interview Lift
resolved cases with interview
Typical timeline
5y 0m
Avg Prosecution
53 currently pending
Career history
274
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
13.7%
-26.3% vs TC avg
§112
26.1%
-13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 221 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-8,10,12 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Tohyama et al. (US 6451740;09/17/2002). Tohyama et al. teach at abstract the uracil compound of formula I: “ PNG media_image1.png 432 478 media_image1.png Greyscale ” Tohyama et al. table 5 at column 94 teach uracil compound S-27 which reads on instant compound of formula I where X1 is Br: X3 is H: X4 is H and A is OCH2CO2CH2CH3 suggesting the instantly claimed uracil compound; Z is phenyl; X is oxygen; Z is phenyl; Q is oxygen. Tohyama et al. at claims 32-36 the combination of the uracil compound being combined with an inert carrier or a diluent to yield a herbicidal composition. Tohyama et al.at the claims teach a method of applying the herbicidal composition onto weeds(undesirable vegetation to control weed growth. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALTON NATHANIEL PRYOR whose telephone number is (571)272-0621. The examiner can normally be reached 7-4:00 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Liu Sue can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALTON N PRYOR/ Primary Examiner, Art Unit 1616
Read full office action

Prosecution Timeline

Sep 01, 2022
Application Filed
Sep 06, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599568
SOFTGEL CAPSULES HAVING A FILL COMPOSITION COMPRISING MAGNESIUM OXIDE
2y 5m to grant Granted Apr 14, 2026
Patent 12577319
Anti-trop2 Antibody
2y 5m to grant Granted Mar 17, 2026
Patent 12570763
AEROSOLIZED MUCUS-TETHERING NANOBODIES TO PROTECT AGAINST VIRAL AND MICROBIAL CONTAMINATION IN CLOSED AND SEMI-ENCLOSED SPACES
2y 5m to grant Granted Mar 10, 2026
Patent 12565528
LAG-3 ANTAGONIST THERAPY FOR LUNG CANCER
2y 5m to grant Granted Mar 03, 2026
Patent 12522666
CD22 TARGETING-MOIETY FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
21%
Grant Probability
34%
With Interview (+12.9%)
5y 0m
Median Time to Grant
Low
PTA Risk
Based on 221 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month